Purpose To evaluate the efficacy and safety of Artisan-Verysise intraocular lens (IOL) secondarily implanted for aphakic correction in post-traumatic vitrectomized eyes. Methods Postoperative outcomes of secondary implantation of an iris-supported Artisan IOL in 17 unilateral aphakic patients with previous pars plana vitrectomy secondary to posterior segment trauma were evaluated prospectively. Eyes had vitrectomized in previous 6-60 months. After complete ophthalmologic examination, IOL implantation was performed through a scleral tunnel incision. Patients were followed for visual outcome, endothelial cell density (ECD) and occurrence of complications. Uncorrected visual acuity (UCVA), best-corrected visual acuity (BCVA), spherical equivalents (SE), and ECD were compared before and after IOL insertion. Conclusion Secondary Artisan IOL implantation is an effective and safe procedure to correct aphakia in vitrectomized eyes without capsular support after trauma. Considering good visual rehabilitation and low rate of complications, this procedure is recommended in vitrectomized eyes.

Background: To evaluate and compare the effect of different doses of subconjunctival bevacizumab with betamethasone on the development of corneal major new vessels in a rat model of corneal chemical injury. Methods: The right eyes of 100 male Sprague-Dawley rats were randomly divided into 10 experimental groups (n = 10 per group). Chemical cauterization of the cornea was performed by using silver nitrate/potassium nitrate sticks. Immediately following corneal cauterization, the animals in groups 1–5 received subconjunctival injections of 0.02 ml of normal saline (control A), betamethasone LA (6 mg/ml) and different doses of bevacizumab (1, 5 and 25 mg/ml), respectively. In another experiment, the animals in groups 6–10 received subconjunctival injections of 0.02 ml of normal saline (control B), betamethasone LA (6 mg/ml) and different doses of bevacizumab (1, 5 and 25 mg/ml), respectively, 7 days following corneal cauterization. The numbers of major thick-walled vessels originating from the limbus reaching the corneal scar were counted 7 days after corneal cauterization in groups 1–5 and 14 days after corneal cauterization in groups 6–10. Results: The number of major vessels in groups 1–5 was 19.63 ± 3.77, 17.25 ± 5.33, 16.10 ± 5.02, 12.89 ± 2.70 and 12.36 ± 4.45 when assessed 7 days after corneal cauterization, respectively. Administration of betamethasone in group 2 had no significant effect on the corneal major vessel count compared to control A. The number of major vessels in groups 4 and 5 (bevacizumab 5 and 25 mg/ml) was significantly lower than that of group 1 (p < 0.01, Student’s t test). The number of vessels in groups 6–10 was 12.55 ± 5.64, 11.30 ± 9.33, 5.50 ± 6.34, 2.73 ± 4.73 and 2.67 ± 3.77 when assessed 14 days after corneal cauterization, respectively. Subconjunctival administration of betamethasone 7 days after corneal cauterization did not reduce the amount of corneal major vessels compared to control B. Administration of 0.02 ml of bevacizumab in doses of 1, 5 and 25 mg/ml 7 days after corneal cauterization significantly reduced the amount of major vessels compared to group 6 (p = 0.01, p < 0.01 and p < 0.01, respectively). There was no significant difference in percent area of corneal scar between different groups. Conclusion: Single subconjunctival injection of bevacizumab is efficacious in the prevention of formation as well as regression of major vessels compared to betamethasone in this rat model of corneal neovascularization. Even lower doses of bevacizumab might be efficacious.